The CASP6 Knockout PaTu 8988t Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the human pancreatic ductal adenocarcinoma cell line PaTu 8988t, featuring stable disruption of the CASP6 gene. This heterogeneous knockout pool is generated by non-viral delivery of Cas9 and guide RNA complexes, resulting in a mixed population of cells carrying diverse loss-of-function mutations at the target locus. The polyclonal format preserves allelic diversity and avoids clonal selection bias, offering a physiologically relevant model for studying CASP6 function without the confounding effects of single-cell-derived artifacts.
PaTu 8988t is a human pancreatic ductal adenocarcinoma cell line established from a liver metastasis, serving as a clinically relevant model for metastatic pancreatic cancer. It exhibits aggressive growth, invasive properties, and hallmark oncogenic alterations, providing an ideal platform to investigate how apoptosis executioners influence tumor progression and drug susceptibility in advanced disease.
CASP6 encodes the executioner caspase-6, a downstream effector protease activated by initiator caspases such as CASP8 and CASP9 in response to extrinsic (FasL/TNF) or intrinsic (cytochrome c/Apaf-1) death signals, and is also cross-activated by CASP3 and CASP7. Once active, caspase-6 cleaves nuclear substrates including lamin A/C (LMNA) and PARP1, leading to nuclear envelope breakdown and chromatin fragmentation. Its activity is regulated by inhibitor-of-apoptosis proteins XIAP and cIAP1/2, and it participates in non-apoptotic processes like axonal pruning and neurodegeneration, where interactions with amyloid precursor protein (APP) and cytoskeletal components have been implicated.
In pancreatic adenocarcinoma PaTu 8988t cells, CASP6 knockout enables dissection of its impact on apoptosis sensitivity, metastasis, and therapy resistance. Since apoptotic pathways are often aberrant in pancreatic cancer, this model uncovers compensatory roles of other executioner caspases and illuminates resistance mechanisms to apoptosis-inducing drugs. The dual relevance of CASP6 to neurodegeneration and cancer further permits exploration of shared molecular programs.
These polyclonal knockout cells are suitable for apoptosis assays (Annexin V/PI, TUNEL), western blotting for caspase-6 and its targets (lamin A/C, PARP1), immunofluorescence for nuclear lamin organization, clonogenic survival assays, drug sensitivity profiling, and migration/invasion studies. The mixed population also facilitates pooled CRISPR screens and synthetic lethality experiments. For technical inquiries, please contact Ascent Research.
